Quercetin in prostate cancer: Chemotherapeutic and chemopreventive effects, mechanisms and clinical application potential (Review)
- Authors:
- Feiya Yang
- Liming Song
- Huiping Wang
- Jun Wang
- Zhiqing Xu
- Nianzeng Xing
-
Affiliations: Department of Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, P.R. China, Department of Reproductive Immunology and Pharmacology, National Research Institute for Family Planning, Beijing 100081, P.R. China, Department of Neurosurgery, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China, Institute of Neuroscience, Beijing Key Laboratory of Neural Regeneration and Repair, Capital Medical University, Beijing 100069, P.R. China - Published online on: March 31, 2015 https://doi.org/10.3892/or.2015.3886
- Pages: 2659-2668
This article is mentioned in:
Abstract
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Qu S, Wang K, Xue H and Wang Y, Wu R, Liu C, Gao AC, Gout PW, Collins CC and Wang Y: Enhanced anticancer activity of a combination of docetaxel and Aneustat (OMN54) in a patient-derived, advanced prostate cancer tissue xenograft model. Mol Oncol. 8:311–322. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Xing N, Chen Y, Mitchell SH and Young CY: Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Carcinogenesis. 22:409–414. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Wang G, Song L, Wang H and Xing N: Quercetin synergizes with 2-methoxyestradiol inhibiting cell growth and inducing apoptosis in human prostate cancer cells. Oncol Rep. 30:357–363. 2013.PubMed/NCBI | |
|
Sharmila G, Bhat FA, Arunkumar R, Elumalai P, Raja Singh P, Senthilkumar K and Arunakaran J: Chemopreventive effect of quercetin, a natural dietary flavonoid on prostate cancer in in vivo model. Clin Nutr. 33:718–726. 2014. View Article : Google Scholar | |
|
Firdous AB, Sharmila G, Balakrishnan S, RajaSingh P, Suganya S, Srinivasan N and Arunakaran J: Quercetin, a natural dietary flavonoid, acts as a chemopreventive agent against prostate cancer in an in vivo model by inhibiting the EGFR signaling pathway. Food Funct. 5:2632–2645. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Sharmila G, Athirai T, Kiruthiga B, Senthilkumar K, Elumalai P, Arunkumar R and Arunakaran J: Chemopreventive effect of quercetin in MNU and testosterone induced prostate cancer of Sprague-Dawley rats. Nutr Cancer. 66:38–46. 2014. View Article : Google Scholar | |
|
Fleshner N: Defining high-risk prostate cancer: current status. Can J Urol. (Suppl 1): 14–96. 2005.PubMed/NCBI | |
|
Hotte SJ and Saad F: Current management of castrate-resistant prostate cancer. Curr Oncol. 17(Suppl 2): S72–S79. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, et al: TAX 327 Investigators: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 351:1502–1512. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Antonarakis ES and Eisenberger MA: Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences. J Clin Oncol. 31:1709–1712. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
McKeage K: Docetaxel: a review of its use for the first-line treatment of advanced castration-resistant prostate cancer. Drugs. 72:1559–1577. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Bischoff SC: Quercetin: potentials in the prevention and therapy of disease. Curr Opin Clin Nutr Metab Care. 11:733–740. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Graefe EU, Wittig J, Mueller S, Riethling AK, Uehleke B, Drewelow B, Pforte H, Jacobasch G, Derendorf H and Veit M: Pharmacokinetics and bioavailability of quercetin glycosides in humans. J Clin Pharmacol. 41:492–499. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Walle T, Otake Y, Walle UK and Wilson FA: Quercetin glucosides are completely hydrolyzed in ileostomy patients before absorption. J Nutr. 130:2658–2661. 2000.PubMed/NCBI | |
|
Russo GL, Russo M and Spagnuolo C: The pleiotropic flavonoid quercetin: from its metabolism to the inhibition of protein kinases in chronic lymphocytic leukemia. Food Funct. 5:2393–2401. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Kim GT, Lee SH, Kim JI and Kim YM: Quercetin regulates the sestrin 2-AMPK-p38 MAPK signaling pathway and induces apoptosis by increasing the generation of intracellular ROS in a p53-independent manner. Int J Mol Med. 33:863–869. 2014.PubMed/NCBI | |
|
Chan ST, Yang NC, Huang CS, Liao JW and Yeh SL: Quercetin enhances the antitumor activity of trichostatin A through upregulation of p53 protein expression in vitro and in vivo. PLoS One. 8:e542552013. View Article : Google Scholar : PubMed/NCBI | |
|
Piao S, Kang M, Lee YJ, Choi WS, Chun YS, Kwak C and Kim HH: Cytotoxic effects of escin on human castration-resistant prostate cancer cells through the induction of apoptosis and G2/M cell cycle arrest. Urology. 84:982.e1–7. 2014. View Article : Google Scholar | |
|
Mehta RG, Murillo G, Naithani R and Peng X: Cancer chemo-prevention by natural products: how far have we come? Pharm Res. 27:950–961. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Liu KC, Yen CY, Wu RS, Yang JS, Lu HF, Lu KW, Lo C, Chen HY, Tang NY, Wu CC, et al: The roles of endoplasmic reticulum stress and mitochondrial apoptotic signaling pathway in quercetin-mediated cell death of human prostate cancer PC-3 cells. Environ Toxicol. 29:428–439. 2014. View Article : Google Scholar | |
|
Samuel T, Fadlalla K, Mosley L, Katkoori V, Turner T and Manne U: Dual-mode interaction between quercetin and DNA-damaging drugs in cancer cells. Anticancer Res. 32:61–71. 2012.PubMed/NCBI | |
|
Kumar R, Verma V, Jain A, Jain RK, Maikhuri JP and Gupta G: Synergistic chemoprotective mechanisms of dietary phytoestrogens in a select combination against prostate cancer. J Nutr Biochem. 22:723–731. 2011. View Article : Google Scholar | |
|
Noori-Daloii MR, Momeny M, Yousefi M, Shirazi FG, Yaseri M, Motamed N, Kazemialiakbar N and Hashemi S: Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy. Med Oncol. 28:1395–1404. 2011. View Article : Google Scholar | |
|
Haddad AQ, Venkateswaran V, Viswanathan L, Teahan SJ, Fleshner NE and Klotz LH: Novel antiproliferative flavonoids induce cell cycle arrest in human prostate cancer cell lines. Prostate Cancer Prostatic Dis. 9:68–76. 2006. View Article : Google Scholar | |
|
Knowles LM, Zigrossi DA, Tauber RA, Hightower C and Milner JA: Flavonoids suppress androgen-independent human prostate tumor proliferation. Nutr Cancer. 38:116–122. 2000. View Article : Google Scholar | |
|
Kampa M, Hatzoglou A, Notas G, Damianaki A, Bakogeorgou E, Gemetzi C, Kouroumalis E, Martin PM and Castanas E: Wine antioxidant polyphenols inhibit the proliferation of human prostate cancer cell lines. Nutr Cancer. 37:223–233. 2000. View Article : Google Scholar | |
|
Vermeulen K, Van Bockstaele DR and Berneman ZN: Apoptosis: mechanisms and relevance in cancer. Ann Hematol. 84:627–639. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Jung YH, Heo J, Lee YJ, Kwon TK and Kim YH: Quercetin enhances TRAIL-induced apoptosis in prostate cancer cells via increased protein stability of death receptor 5. Life Sci. 86:351–357. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Kim YH, Lee DH, Jeong JH, Guo ZS and Lee YJ: Quercetin augments TRAIL-induced apoptotic death: involvement of the ERK signal transduction pathway. Biochem Pharmacol. 75:1946–1958. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Kim YH and Lee YJ: TRAIL apoptosis is enhanced by quercetin through Akt dephosphorylation. J Cell Biochem. 100:998–1009. 2007. View Article : Google Scholar | |
|
Lee DH, Szczepanski M and Lee YJ: Role of Bax in quercetin-induced apoptosis in human prostate cancer cells. Biochem Pharmacol. 75:2345–2355. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Senthilkumar K, Elumalai P, Arunkumar R, Banudevi S, Gunadharini ND, Sharmila G, Selvakumar K and Arunakaran J: Quercetin regulates insulin like growth factor signaling and induces intrinsic and extrinsic pathway mediated apoptosis in androgen independent prostate cancer cells (PC-3). Mol Cell Biochem. 344:173–184. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Xu R, Zhang Y, Ye X, Xue S, Shi J, Pan J and Chen Q: Inhibition effects and induction of apoptosis of flavonoids on the prostate cancer cell line PC-3 in vitro. Food Chem. 138:48–53. 2013. View Article : Google Scholar | |
|
Wang P, Heber D and Henning SM: Quercetin increased the anti-proliferative activity of green tea polyphenol (-)-epigallocatechin gallate in prostate cancer cells. Nutr Cancer. 64:580–587. 2012. View Article : Google Scholar : | |
|
Vijayababu MR, Kanagaraj P, Arunkumar A, Ilangovan R, Aruldhas MM and Arunakaran J: Quercetin-induced growth inhibition and cell death in prostatic carcinoma cells (PC-3) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression. J Cancer Res Clin Oncol. 131:765–771. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Shenouda NS, Zhou C, Browning JD, Ansell PJ, Sakla MS, Lubahn DB and Macdonald RS: Phytoestrogens in common herbs regulate prostate cancer cell growth in vitro. Nutr Cancer. 49:200–208. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Eder IE, Culig Z, Putz T, Nessler-Menardi C, Bartsch G and Klocker H: Molecular biology of the androgen receptor: from molecular understanding to the clinic. Eur Urol. 40:241–251. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Culig Z, Klocker H, Bartsch G and Hobisch A: Androgen receptors in prostate cancer. Endocr Relat Cancer. 9:155–170. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Devlin HL and Mudryj M: Progression of prostate cancer: multiple pathways to androgen independence. Cancer Lett. 274:177–86. 2009. View Article : Google Scholar | |
|
Culig Z and Bartsch G: Androgen axis in prostate cancer. J Cell Biochem. 99:373–381. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Yuan H, Young CY, Tian Y, Liu Z, Zhang M and Lou H: Suppression of the androgen receptor function by quercetin through protein-protein interactions of Sp1, c-Jun, and the androgen receptor in human prostate cancer cells. Mol Cell Biochem. 339:253–262. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Ferruelo A, Romero I, Cabrera PM, Arance I, Andrés G and Angulo JC: Effects of resveratrol and other wine polyphenols on the proliferation, apoptosis and androgen receptor expression in LNCaP cells. Actas Urol Esp. 38:397–404. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Yuan H, Pan Y and Young CYF: Overexpression of c-Jun induced by quercetin and resverol inhibits the expression and function of the androgen receptor in human prostate cancer cells. Cancer Lett. 213:155–163. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Yuan HQ, Guo HF, He ML, Kong F, Hu XY, Jiang AL, Xu X, Zhang JY and Charles YF: The roles of c-Jun and CBP in the inhibitory effect of quercetin on prostate cancer cells. Yao Xue Xue Bao. 41:819–824. 2006.In Chinese. PubMed/NCBI | |
|
Yuan H, Gong A and Young CY: Involvement of transcription factor Sp1 in quercetin-mediated inhibitory effect on the androgen receptor in human prostate cancer cells. Carcinogenesis. 26:793–801. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Britton RG, Horner-Glister E, Pomenya OA, Smith EE, Denton R, Jenkins PR, Steward WP, Brown K, Gescher A and Sale S: Synthesis and biological evaluation of novel flavonols as potential anti-prostate cancer agents. Eur J Med Chem. 54:952–958. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Hsieh TC and Wu JM: Targeting CWR22Rv1 prostate cancer cell proliferation and gene expression by combinations of the phytochemicals EGCG, genistein and quercetin. Anticancer Res. 29:4025–4032. 2009.PubMed/NCBI | |
|
Morris JD, Pramanik R, Zhang X, Carey AM, Ragavan N, Martin FL and Muir GH: Selenium- or quercetin-induced retardation of DNA synthesis in primary prostate cells occurs in the presence of a concomitant reduction in androgen-receptor activity. Cancer Lett. 239:111–122. 2006. View Article : Google Scholar | |
|
Morgan TM, Koreckij TD and Corey E: Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. Curr Cancer Drug Targets. 9:237–249. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Cohen MB and Rokhlin OW: Mechanisms of prostate cancer cell survival after inhibition of AR expression. J Cell Biochem. 106:363–371. 2009. View Article : Google Scholar | |
|
Baiz D, Pinder TA, Hassan S, Karpova Y, Salsbury F, Welker ME and Kulik G: Synthesis and characterization of a novel prostate cancer-targeted phosphatidylinositol-3-kinase inhibitor prodrug. J Med Chem. 55:8038–8046. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Pratheeshkumar P, Budhraja A, Son YO, Wang X, Zhang Z, Ding S, Wang L, Hitron A, Lee JC, Xu M, et al: Quercetin inhibits angiogenesis mediated human prostate tumor growth by targeting VEGFR-2 regulated AKT/mTOR/P70S6K signaling pathways. PLoS One. 7:e475162012. View Article : Google Scholar | |
|
Yu PC, Gu SY, Bu JW and Du JL: TRPC1 is essential for in vivo angiogenesis in zebrafish. Circ Res. 106:1221–1232. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Potente M, Gerhardt H and Carmeliet P: Basic and therapeutic aspects of angiogenesis. Cell. 146:873–887. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ and Holash J: Vascular-specific growth factors and blood vessel formation. Nature. 407:242–248. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Risau W: Mechanisms of angiogenesis. Nature. 386:671–674. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Oh SJ, Kim O, Lee JS, Kim JA, Kim MR, Choi HS, Shim JH, Kang KW and Kim YC: Inhibition of angiogenesis by quercetin in tamoxifen-resistant breast cancer cells. Food Chem Toxicol. 48:3227–3234. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Matei D, Schilder J, Sutton G, Perkins S, Breen T, Quon C and Sidor C: Activity of 2 methoxyestradiol (Panzem NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial. Gynecol Oncol. 115:90–96. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Chen Y, Li XX, Xing NZ and Cao XG: Quercetin inhibits choroidal and retinal angiogenesis in vitro. Graefes Arch Clin Exp Ophthalmol. 246:373–378. 2008. View Article : Google Scholar | |
|
Lee DH and Lee YJ: Quercetin suppresses hypoxia-induced accumulation of hypoxia-inducible factor-1alpha (HIF-1alpha) through inhibiting protein synthesis. J Cell Biochem. 105:546–553. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Shimada M, Hernandez-Gonzalez I, Gonzalez-Robayna I and Richards JS: Paracrine and autocrine regulation of epidermal growth factor-like factors in cumulus oocyte complexes and granulosa cells: key roles for prostaglandin synthase 2 and progesterone receptor. Mol Endocrinol. 20:1352–1365. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Gioeli D, Mandell JW, Petroni GR, Frierson HF Jr and Weber MJ: Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res. 59:279–284. 1999.PubMed/NCBI | |
|
Price DT, Della Rocca G, Guo C, Ballo MS, Schwinn DA and Luttrell LM: Activation of extracellular signal-regulated kinase in human prostate cancer. J Urol. 162:1537–1542. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Shimada K, Nakamura M, Ishida E, Kishi M and Konishi N: Roles of p38- and c-jun NH2-terminal kinase-mediated pathways in 2-methoxyestradiol-induced p53 induction and apoptosis. Carcinogenesis. 24:1067–1075. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Senthilkumar K, Arunkumar R, Elumalai P, Sharmila G, Gunadharini DN, Banudevi S, Krishnamoorthy G, Benson CS and Arunakaran J: Quercetin inhibits invasion, migration and signalling molecules involved in cell survival and proliferation of prostate cancer cell line (PC-3). Cell Biochem Funct. 29:87–95. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Cox ME, Gleave ME, Zakikhani M, Bell RH, Piura E, Vickers E, Cunningham M, Larsson O, Fazli L and Pollak M: Insulin receptor expression by human prostate cancers. Prostate. 69:33–40. 2009. View Article : Google Scholar | |
|
Nickerson T, Chang F, Lorimer D, Smeekens SP, Sawyers CL and Pollak M: In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res. 61:6276–6280. 2001.PubMed/NCBI | |
|
Vijayababu MR, Kanagaraj P, Arunkumar A, Ilangovan R, Dharmarajan A and Arunakaran J: Quercetin induces p53-independent apoptosis in human prostate cancer cells by modulating Bcl-2-related proteins: a possible mediation by IGFBP-3. Oncol Res. 16:67–74. 2006.PubMed/NCBI | |
|
Vijayababu MR, Arunkumar A, Kanagaraj P and Arunakaran J: Effects of quercetin on insulin-like growth factors (IGFs) and their binding protein-3 (IGFBP-3) secretion and induction of apoptosis in human prostate cancer cells. J Carcinog. 5:102006. View Article : Google Scholar : PubMed/NCBI | |
|
Wang S, DeGroff VL and Clinton SK: Tomato and soy poly-phenols reduce insulin-like growth factor-I-stimulated rat prostate cancer cell proliferation and apoptotic resistance in vitro via inhibition of intracellular signaling pathways involving tyrosine kinase. J Nutr. 133:2367–2376. 2003.PubMed/NCBI | |
|
Bhat FA, Sharmila G, Balakrishnan S, Arunkumar R, Elumalai P, Suganya S, Raja Singh P, Srinivasan N and Arunakaran J: Quercetin reverses EGF-induced epithelial to mesenchymal transition and invasiveness in prostate cancer (PC-3) cell line via EGFR/PI3K/Akt pathway. J Nutr Biochem. 25:1132–1139. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Tang SN, Singh C, Nall D, Meeker D, Shankar S and Srivastava RK: The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition. J Mol Signal. 5:142010. View Article : Google Scholar : PubMed/NCBI | |
|
Ko CC, Chen YJ, Chen CT, Liu YC, Cheng FC, Hsu KC and Chow LP: Chemical proteomics identifies heterogeneous nuclear ribonucleoprotein (hnRNP) A1 as the molecular target of quercetin in its anti-cancer effects in PC-3 cells. J Biol Chem. 289:22078–22089. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Ferruelo A, de Las Heras MM, Redondo C, Ramón de Fata F, Romero I and Angulo JC: Wine polyphenols exert antineoplasic effect on androgen resistant PC-3 cell line through the inhibition of the transcriptional activity of COX-2 promoter mediated by NF-κB. Actas Urol Esp. 38:429–437. 2014.In English and Spanish. View Article : Google Scholar : PubMed/NCBI | |
|
Slusarz A, Shenouda NS, Sakla MS, Drenkhahn SK, Narula AS, MacDonald RS, Besch-Williford CL and Lubahn DB: Common botanical compounds inhibit the hedgehog signaling pathway in prostate cancer. Cancer Res. 70:3382–3390. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Nair HK, Rao KV, Aalinkeel R, Mahajan S, Chawda R and Schwartz SA: Inhibition of prostate cancer cell colony formation by the flavonoid quercetin correlates with modulation of specific regulatory genes. Clin Diagn Lab Immunol. 11:63–69. 2004.PubMed/NCBI | |
|
Bandyopadhyay S, Romero JR and Chattopadhyay N: Kaempferol and quercetin stimulate granulocyte-macrophage colony-stimulating factor secretion in human prostate cancer cells. Mol Cell Endocrinol. 287:57–64. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Aalinkeel R, Bindukumar B, Reynolds JL, Sykes DE, Mahajan SD, Chadha KC and Schwartz SA: The dietary bioflavonoid, quercetin, selectively induces apoptosis of prostate cancer cells by down-regulating the expression of heat shock protein 90. Prostate. 68:1773–1789. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Jones EL, Zhao MJ, Stevenson MA and Calderwood SK: The 70 kilodalton heat shock protein is an inhibitor of apoptosis in prostate cancer. Int J Hyperthermia. 20:835–849. 2004. View Article : Google Scholar | |
|
Nakanoma T, Ueno M, Iida M, Hirata R and Deguchi N: Effects of quercetin on the heat-induced cytotoxicity of prostate cancer cells. Int J Urol. 8:623–630. 2001. View Article : Google Scholar | |
|
Asea A, Ara G, Teicher BA, Stevenson MA and Calderwood SK: Effects of the flavonoid drug quercetin on the response of human prostate tumours to hyperthermia in vitro and in vivo. Int J Hyperthermia. 17:347–356. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Vijayababu MR, Arunkumar A, Kanagaraj P, Venkataraman P, Krishnamoorthy G and Arunakaran J: Quercetin downregulates matrix metalloproteinases 2 and 9 proteins expression in prostate cancer cells (PC-3). Mol Cell Biochem. 287:109–116. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Chaudhary A and Willett KL: Inhibition of human cytochrome CYP 1 enzymes by flavonoids of St. John’s wort. Toxicology. 217:194–205. 2006. View Article : Google Scholar | |
|
Brusselmans K, Vrolix R, Verhoeven G and Swinnen JV: Induction of cancer cell apoptosis by flavonoids is associated with their ability to inhibit fatty acid synthase activity. J Biol Chem. 280:5636–5645. 2005. View Article : Google Scholar | |
|
Huynh H, Nguyen TT, Chan E and Tran E: Inhibition of ErbB-2 and ErbB-3 expression by quercetin prevents transforming growth factor α (TGF-α)- and epidermal growth factor (EGF)-induced human PC-3 prostate cancer cell proliferation. Int J Oncol. 23:821–829. 2003.PubMed/NCBI | |
|
Ma ZS, Huynh TH, Ng CP, Do PT, Nguyen TH and Huynh H: Reduction of CWR22 prostate tumor xenograft growth by combined tamoxifenquercetin treatment is associated with inhibition of angiogenesis and cellular proliferation. Int J Oncol. 24:1297–1304. 2004.PubMed/NCBI | |
|
Wang P, Vadgama JV, Said JW, Magyar CE, Doan N, Heber D and Henning SM: Enhanced inhibition of prostate cancer xenograft tumor growth by combining quercetin and green tea. J Nutr Biochem. 25:73–80. 2014. View Article : Google Scholar | |
|
Ma Z, Hung Nguyen T, Hoa Huynh T, Tien Do P and Huynh H: Reduction of rat prostate weight by combined quercetin-finasteride treatment is associated with cell cycle deregulation. J Endocrinol. 181:493–507. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Xiao ZP, Peng ZY, Peng MJ, Yan WB, Ouyang YZ and Zhu HL: Flavonoids health benefits and their molecular mechanism. Mini Rev Med Chem. 11:169–177. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Szliszka E and Krol W: The role of dietary polyphenols in tumor necrosis factor-related apoptosis inducing ligand (TRAIL)-induced apoptosis for cancer chemoprevention. Eur J Cancer Prev. 20:63–69. 2011. View Article : Google Scholar | |
|
Leonarduzzi G, Testa G, Sottero B, Gamba P and Poli G: Design and development of nanovehicle-based delivery systems for preventive or therapeutic supplementation with flavonoids. Curr Med Chem. 17:74–95. 2010. View Article : Google Scholar | |
|
Klingeler R, Hampel S and Büchner B: Carbon nanotube based biomedical agents for heating, temperature sensoring and drug delivery. Int J Hyperther. 24:496–505. 2008. View Article : Google Scholar | |
|
Cirillo G, Vittorio O, Hampel S, Iemma F, Parchi P, Cecchini M, Puoci F and Picci N: Quercetin nanocomposite as novel anticancer therapeutic: improved efficiency and reduced toxicity. Eur J Pharm Sci. 49:359–365. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Forbes AM, Lin H, Meadows GG and Meier GP: Synthesis and anticancer activity of new flavonoid analogs and inconsistencies in assays related to proliferation and viability measurements. Int J Oncol. 45:831–842. 2014.PubMed/NCBI | |
|
Paliwal S, Sundaram J and Mitragotri S: Induction of cancer-specific cytotoxicity towards human prostate and skin cells using quercetin and ultrasound. Br J Cancer. 92:499–502. 2005.PubMed/NCBI | |
|
Lund L, Svolgaard N and Poulsen MH: Prostate cancer: a review of active surveillance. Res Rep Urol. 6:107–112. 2014.PubMed/NCBI | |
|
Sakr WA, Haas GP, Cassin BF, Pontes JE and Crissman JD: The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol. 150:379–385. 1993.PubMed/NCBI | |
|
Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, et al: Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 350:2239–2246. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Ting H, Deep G, Agarwal C and Agarwal R: The strategies to control prostate cancer by chemoprevention approaches. Mutat Res Fundam Mol Mech Mutagen. 760:1–15. 2014. View Article : Google Scholar | |
|
Wang Z, Fan J, Liu M, Yeung S, Chang A, Chow MS, Pon D and Huang Y: Nutraceuticals for prostate cancer chemoprevention: from molecular mechanisms to clinical application. Expert Opin Investig Drugs. 22:1613–1626. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Hsing AW, Tsao L and Devesa SS: International trends and patterns of prostate cancer incidence and mortality. Int J Cancer. 85:60–67. 2000. View Article : Google Scholar | |
|
Cook LS, Goldoft M, Schwartz SM and Weiss NS: Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States and their descendants. J Urol. 161:152–155. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Chaudhary A, Pechan T and Willett KL: Differential protein expression of peroxiredoxin I and II by benzo(a)pyrene and quercetin treatment in 22Rv1 and PrEC prostate cell lines. Toxicol Appl Pharmacol. 220:197–210. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Gugler R, Leschik M and Dengler HJ: Disposition of quercetin in man after single oral and intravenous doses. Eur J Clin Pharmacol. 9:229–234. 1975. View Article : Google Scholar : PubMed/NCBI | |
|
Ferry DR, Smith A, Malkhandi J, Fyfe DW, de Takats PG, Anderson D, Baker J and Kerr DJ: Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res. 2:659–668. 1996.PubMed/NCBI | |
|
Egert S, Wolffram S, Bosy-Westphal A, Boesch-Saadatmandi C, Wagner AE, Frank J, Rimbach G and Mueller MJ: Daily quercetin supplementation dose-dependently increases plasma quercetin concentrations in healthy humans. J Nutr. 138:1615–1621. 2008.PubMed/NCBI | |
|
Utesch D, Feige K, Dasenbrock J, Broschard TH, Harwood M, Danielewska-Nikiel B and Lines TC: Evaluation of the potential in vivo genotoxicity of quercetin. Mutat Res. 654:38–44. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Shoskes DA, Zeitlin SI, Shahed A and Rajfer J: Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial. Urology. 54:960–963. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Cialdella-Kam L, Nieman DC, Sha W, Meaney MP, Knab AM and Shanely RA: Dose-response to 3 months of quercetin-containing supplements on metabolite and quercetin conjugate profile in adults. Br J Nutr. 109:1923–1933. 2013. View Article : Google Scholar | |
|
McCann SE, Ambrosone CB, Moysich KB, Brasure J, Marshall JR, Freudenheim JL, Wilkinson GS and Graham S: Intakes of selected nutrients, foods, and phytochemicals and prostate cancer risk in Western New York. Nutr Cancer. 53:33–41. 2005. View Article : Google Scholar : PubMed/NCBI |
